The Valley Desk

Clinical trial reportJCO precision oncologyPublished

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
JCO precision oncology
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Antineoplastic Agents; Mutation; Antibodies, Monoclonal, Humanized; Trastuzumab; Erb-b2 Receptor Tyrosine Kinases
PubMed ID
37315265
Added to directory
Source checked

Report a correction or request removal